BWM
ABCL icon

Baystate Wealth Management’s AbCellera Biologics ABCL Stock Holding History

Baystate Wealth Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$2.85K Buy
+500
New +$2.32K ﹤0.01% 1004

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

Baystate Wealth Management's ABCL Position: Q4 2023 in Review

Baystate Wealth Management opened a new position in AbCellera Biologics (ABCL) in Q4 2023: 500 shares worth $2.85K. The stake represents ﹤0.01% of the portfolio and ranks #1004 among its holdings.

142 funds tracked by Wall St. Rank hold ABCL as of Q4 2023.

  • Baystate Wealth Management held 500 shares of AbCellera Biologics worth $2.85K as of Q4 2023.
  • AbCellera Biologics was a new Baystate Wealth Management position in Q4 2023.
  • AbCellera Biologics made up ﹤0.01% of Baystate Wealth Management's portfolio in Q4 2023, its #1004 holding.
  • 142 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2023.

Based on Baystate Wealth Management's 13F filing for Q4 2023, filed 29 Jan 2024.